A2-AiAnn Arbor, Michigan, United States
Disclosure information not submitted.
ORF32-01 - Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients with Classic Congenital Adrenal Hyperplasia
Sunday, June 14, 20261:45 PM - 1:50 PM CT
MON-494 - Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients with Classic Congenital Adrenal Hyperplasia
Monday, June 15, 20269:00 AM - 2:00 PM CT